Keywords: Ranbaxy, Lulifin launch, India, Summit Pharmaceutical, Dermatology

Ranbaxy launches Lulifin, in-licensed from Summit Pharmaceuticals, in India

Article | 05 January 2010

Print This

Indian drugmaker Ranbaxy Laboratories, which is majority owned by Japan’s Daiichi Sankyo, has launched a New Chemical Entity drug, ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in